Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 3FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Classical hematology 5Gynecologic 3Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

olaparib 4liposomal doxorubicin 1iniparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Fanconi Anemia, Complementation Group D1 × Clear all
NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

AstraZeneca

Phase 2 Completed
265 enrolled 25 charts 1 FDA
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

AstraZeneca

Phase 2 Completed
54 enrolled 17 charts
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT00628251 2019-12-05

ICEBERG 3

AstraZeneca

Phase 2 Completed
97 enrolled 22 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

AstraZeneca

Phase 2 Completed
58 enrolled 13 charts
Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00677079 2013-10-01

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sanofi

Phase 2 Completed
12 enrolled
Classical hematology

Fanconi Anemia, Complementation Group D1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡